Clinical Trials Logo

Clinical Trial Summary

This was a Phase 1, randomized, double-blind, placebo-controlled, single and multiple ascending dose study of the safety, tolerability, and pharmacokinetics of Minocin (minocycline) for injection in healthy adult participants.


Clinical Trial Description

The purpose of this study was to collect safety, tolerability, and pharmacokinetic (PK) data on ascending dose regimens of Minocin (minocycline) for Injection. The safety, tolerability, and PK data was to support the compound as a potential clinical candidate in Europe and allow recommendations of dose levels to be used in future Phase 2/3 studies. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02802631
Study type Interventional
Source Melinta Therapeutics, Inc.
Contact
Status Completed
Phase Phase 1
Start date April 20, 2017
Completion date February 8, 2018

See also
  Status Clinical Trial Phase
Completed NCT05019950 - Safety Tolerability and Pharmacokinetics of Oral NIM-1324 in Healthy Adult Male and Female Volunteers Phase 1
Completed NCT01366339 - Tolerance and Pharmacokinetics Study of MNTX Tablets Phase 1
Completed NCT01862835 - Impact of Estradiol Addback Phase 1
Completed NCT01629446 - Lofexidine Mass Balance in Volunteers Phase 1
Completed NCT02026973 - Impact of Endogenous E2 on SSI and GH Rebound Phase 1
Completed NCT03860571 - Safety, Tolerability, and Pharmacokinetics of Oral BT-11 in Healthy Adult Male and Female Volunteers Phase 1
Recruiting NCT03234504 - Development and Validation of a Novel Stereoacuity Test Using Head-mounted Display
Completed NCT04188730 - A Study Evaluating the Relative Bioavailability of Lofexidine Granules for Reconstitution Compared to LUCEMYRA (Lofexidine) Tablets and the Effect of Food on the Bioavailability of the Lofexidine Granules for Reconstitution Phase 1
Completed NCT02271282 - Estradiol-Receptor Blockade in Older Men and Women Phase 1
Withdrawn NCT03291158 - Safety and PK Trial Evaluating the Plasma, Epithelial Lining Fluid, and Alveolar Macrophage Concentrations of Minocin IV Phase 1